Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 2674 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Repligen initiates Phase IIb bipolar depression trial

This Phase IIb study is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or placebo twice daily